Testing for her2 in breast cancer: current pathology challenges faced in Canada.

Item

http://www.wikidata.org/entity/Q36416223

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@ast

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@en

type

Item

label

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@ast

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@en

prefLabel

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@ast

Testing for her2 in breast cancer: current pathology challenges faced in Canada.

@en

P1476

Testing for her2 in breast cancer: current pathology challenges faced in Canada

@en

P2093

A Magliocco

http://www.w3.org/2001/XMLSchema#string

B Gilks

http://www.w3.org/2001/XMLSchema#string

D Pilavdzic

http://www.w3.org/2001/XMLSchema#string

H Rees

http://www.w3.org/2001/XMLSchema#string

L Elavathil

http://www.w3.org/2001/XMLSchema#string

M Chang

http://www.w3.org/2001/XMLSchema#string

N Miller

http://www.w3.org/2001/XMLSchema#string

N Pettigrew

http://www.w3.org/2001/XMLSchema#string

P Barnes

http://www.w3.org/2001/XMLSchema#string

R Berendt

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

Optimizing the management of HER2-positive early breast cancer: the clinical reality.

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.

Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations

P304

315-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.19.1173

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anna Marie Mulligan

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234089955

http://www.w3.org/2001/XMLSchema#string

P698

23300357

http://www.w3.org/2001/XMLSchema#string

P921

Canada

P932

3503664

http://www.w3.org/2001/XMLSchema#string